Nicolas Palaskas1, Kara Thompson1, Gregory Gladish2, Ali M Agha3, Saamir Hassan1, Cezar Iliescu1, Peter Kim1, Jean B Durand1, Juan C Lopez-Mattei4,5. 1. Department of Cardiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1451, Houston, TX, 77030, USA. 2. Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA. 4. Department of Cardiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1451, Houston, TX, 77030, USA. jlopez9@mdanderson.org. 5. Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jlopez9@mdanderson.org.
Abstract
PURPOSE OF REVIEW: Our purpose is to discuss the importance of multimodality imaging in the assessment of cardiac tumors and management. We have compiled a recent review of the scientific literature and embedded our clinical pathways and recommendations based on data and clinical experience. RECENT FINDINGS: The use of contrast echocardiography in the assessment of cardiac masses has been shown to be helpful in distinguishing tumor from thrombus. Deformation imaging of cardiac tumors has been shown to differentiate better rhabdomyomas from fibromas in pediatric patients. Cardiac MRI (CMR) appears to be helpful in determining whether cardiac tumors are benign or malignant by identifying presence of infiltration, uptake of contrast in first pass perfusion and gadolinium enhancement. Patients with evidence of cardiac metastases by CMR show similar survival to stage IV cancer without cardiac metastases. In our institution, we use a standardized approach for the evaluation of cardiac masses, which includes multimodality imaging in the appropriate clinical context. The autotransplantation surgical technique has shown some promise in improving survival in patients with primary cardiac sarcomas. In our institution, we do not routinely recommend anticoagulation for "tumor-thrombus" in renal cell carcinoma due to risk of bleeding from primary tumor. Cardiac masses are often found incidentally, but sometimes can present with cardiovascular symptoms due to obstruction and valvular dysfunction, which may prompt imaging. It is important to determine whether the mass is a normal variant, imaging artifact, vegetation, thrombus, or tumor. Transthoracic echocardiography is ideally suited to be the initial imaging modality because of the portability, wide availability, lack of radiation, and relatively low cost. The gold standard cardiac imaging technique to distinguish tumor from thrombus is contrast enhanced CMR with prolonged inversion time. Advantages of CMR when compared to echocardiography regarding characterization of cardiac tumors are as follows: larger field of view, better spatial resolution, better tissue characterization, lack of attenuation, and ability to image at any prescribed plane. Primary and secondary cardiac tumors have particular characteristics in echocardiography and CMR. Imaging of cardiac tumors plays an important role in establishing a diagnosis and in planning management.
PURPOSE OF REVIEW: Our purpose is to discuss the importance of multimodality imaging in the assessment of cardiac tumors and management. We have compiled a recent review of the scientific literature and embedded our clinical pathways and recommendations based on data and clinical experience. RECENT FINDINGS: The use of contrast echocardiography in the assessment of cardiac masses has been shown to be helpful in distinguishing tumor from thrombus. Deformation imaging of cardiac tumors has been shown to differentiate better rhabdomyomas from fibromas in pediatric patients. Cardiac MRI (CMR) appears to be helpful in determining whether cardiac tumors are benign or malignant by identifying presence of infiltration, uptake of contrast in first pass perfusion and gadolinium enhancement. Patients with evidence of cardiac metastases by CMR show similar survival to stage IV cancer without cardiac metastases. In our institution, we use a standardized approach for the evaluation of cardiac masses, which includes multimodality imaging in the appropriate clinical context. The autotransplantation surgical technique has shown some promise in improving survival in patients with primary cardiac sarcomas. In our institution, we do not routinely recommend anticoagulation for "tumor-thrombus" in renal cell carcinoma due to risk of bleeding from primary tumor. Cardiac masses are often found incidentally, but sometimes can present with cardiovascular symptoms due to obstruction and valvular dysfunction, which may prompt imaging. It is important to determine whether the mass is a normal variant, imaging artifact, vegetation, thrombus, or tumor. Transthoracic echocardiography is ideally suited to be the initial imaging modality because of the portability, wide availability, lack of radiation, and relatively low cost. The gold standard cardiac imaging technique to distinguish tumor from thrombus is contrast enhanced CMR with prolonged inversion time. Advantages of CMR when compared to echocardiography regarding characterization of cardiac tumors are as follows: larger field of view, better spatial resolution, better tissue characterization, lack of attenuation, and ability to image at any prescribed plane. Primary and secondary cardiac tumors have particular characteristics in echocardiography and CMR. Imaging of cardiac tumors plays an important role in establishing a diagnosis and in planning management.
Authors: Daniel Y Woodruff; Peter Van Veldhuizen; Gregory Muehlebach; Phillip Johnson; Timothy Williamson; Jeffrey M Holzbeierlein Journal: Urol Oncol Date: 2011-04-21 Impact factor: 3.498
Authors: Jonathan W Weinsaft; Han W Kim; Anna Lisa Crowley; Igor Klem; Chetan Shenoy; Lowie Van Assche; Rhoda Brosnan; Dipan J Shah; Eric J Velazquez; Michele Parker; Robert M Judd; Raymond J Kim Journal: JACC Cardiovasc Imaging Date: 2011-07
Authors: Dumbor L Ngaage; Charles J Mullany; Richard C Daly; Joseph A Dearani; William D Edwards; Henry D Tazelaar; Christopher G A McGregor; Thomas A Orszulak; Francisco J Puga; Hartzell V Schaff; Thoralf M Sundt; Kenton J Zehr Journal: Ann Thorac Surg Date: 2005-11 Impact factor: 4.330
Authors: Philippe B Bertrand; Robert A Levine; Eric M Isselbacher; Pieter M Vandervoort Journal: J Am Soc Echocardiogr Date: 2016-03-09 Impact factor: 5.251
Authors: Austin J Sim; Russell F Palm; Kirby B DeLozier; Vladimir Feygelman; Kujtim Latifi; Gage Redler; Iman R Washington; Evan J Wuthrick; Stephen A Rosenberg Journal: Clin Transl Radiat Oncol Date: 2020-10-31
Authors: Arun Dahiya; Charles Chao; John Younger; Julia Kar; Bryant M Baldwin; Michael V Cohen; Shane Joseph; Anam Chowdhry; Maria S Figarola; Christopher Malozzi; M Farhan Nasser; Yassar Nabeel; Rajiv Shah; J Michael Kennen; Ashish Aneja; Sameh Khalil; Sara Ragab; Omnia Mohammed; Taher Moustafa; Ahmed Hamdy; Shimaa Ahmed; Ahmed Heny; Maha Taher; Madhusudan Ganigara; Arushi Dhar; Nilanjana Misra; Jafar Alzubi; Kurian Pannikottu; Ahmad Jabri; Vinayak Hedge; Anmar Kanaa'n; Joseph Lahorra; Dominique de Waard; David Horne; Santokh Dhillon; Aoife Sweeney; Christian Hamilton-Craig; V S Katikireddi; Allan J Wesley; Chris Hammet; Jason N Johnson; Sylvia S M Chen Journal: J Cardiovasc Magn Reson Date: 2021-04-01 Impact factor: 5.364
Authors: Juan C Lopez-Mattei; Eric H Yang; Maros Ferencik; Lauren A Baldassarre; Susan Dent; Matthew J Budoff Journal: JACC CardioOncol Date: 2021-12-21
Authors: Pritha Subramanyam; Syed S Mahmood; William Dinsfriend; Raymond D Pastore; Peter Martin; Angel T Chan; Jonathan W Weinsaft; Jim W Cheung Journal: JACC CardioOncol Date: 2020-03-17